AU Patent

AU2023384196A1 — Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Assigned to MSN Laboratories Pvt Ltd · Expires 2025-06-12 · 1y expired

What this patent protects

Title of the Invention: Crystalline forms of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)- N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide fumarate and process for its preparation The present invention relates to crystalline forms of N-(4-(6,7-dimethoxyquinolin-4- yloxy)phenyl)-…

USPTO Abstract

Title of the Invention: Crystalline forms of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)- N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide fumarate and process for its preparation The present invention relates to crystalline forms of N-(4-(6,7-dimethoxyquinolin-4- yloxy)phenyl)-N'-(4­fluorophenyl)cyclopropane-1,1-dicarboxamide fumarate represented by the following structural formula-1, and process for its preparation which is referred to as Cabozantinib fumarate. Formula-1 wherein n = 0.25 to 2.0

Drugs covered by this patent

Patent Metadata

Patent number
AU2023384196A1
Jurisdiction
AU
Classification
—
Expires
2025-06-12
Drug substance claim
No
Drug product claim
No
Assignee
MSN Laboratories Pvt Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.